CordenPharma, a contract development and manufacturing organization of active pharmaceutical ingredients (APIs) and drug products, has expanded its commercial oligonucleotide API manufacturing at its CordenPharma Colorado site in Boulder, Colorado.

The expansion, which was completed in the first quarter of 2018, will provide cGMP oligonucleotide manufacturing capacity up to 2 mol, with an increase in total commercial capacity up to 500 kg annually. The facility has also put in place a team of experts with more than 20 years of experience in manufacturing oligonucleotides, according to CordenPharma.

Source: CordenPharma